MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-23-2026
AcelRx Pharmaceuticals EBITDA 2011-2026 | ACRX
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA AcelRx Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -13.5 M | -15.3 M | -16.6 M | -23.7 M | -34 M | -39.1 M | -52.5 M | -35.2 M | -36.9 M | -29.9 M | -17.2 M | -36.8 M | -6.07 M | -29.1 M | -18.8 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -6.07 M | -52.5 M | -27 M |
Quarterly EBITDA AcelRx Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | -5.07 M | - | -5.33 M | -12.7 M | -4.52 M | - | -7.12 M | -8.99 M | -8.69 M | - | -7.57 M | -5.86 M | -15.4 M | - | -12.4 M | -12.6 M | -12 M | - | -8.89 M | -6.86 M | -8.12 M | - | -7.47 M | -8.99 M | -11.6 M | - | -6.43 M | -7.29 M | -8.01 M | - | 8.61 M | -7.13 M | -10.9 M | - | -4.6 M | 318 K | 162 K | - | 439 K | 288 K | 141 K | - | 467 K | 336 K | 164 K | - | 348 K | 232 K | 117 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 8.61 M | -15.4 M | -5.48 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Drug manufacturers industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
6.82 M | - | - | $ 142 M |  USA |
 |
Aerie Pharmaceuticals
AERI
|
-40 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
-19.8 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-23.6 M | - | 0.86 % | $ 117 M | USA |
 |
Aurora Cannabis
ACB
|
-283 M | $ 3.28 | -0.88 % | $ 86.3 M |  Canada |
 |
China Pharma Holdings
CPHI
|
-1.97 M | $ 0.63 | - | $ 11 M |  China |
 |
Catalent
CTLT
|
-260 M | - | - | $ 11.5 B | USA |
 |
Pacira BioSciences
PCRX
|
5.41 M | $ 22.79 | 0.6 % | $ 1.05 B | USA |
 |
Athenex
ATNX
|
-65.5 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-39.7 M | - | - | $ 2.06 B |  France |
 |
Cronos Group
CRON
|
-176 M | $ 2.52 | - | $ 1.33 B | Canada |
 |
DURECT Corporation
DRRX
|
-36.9 M | - | - | $ 50.1 M | USA |
 |
Emergent BioSolutions
EBS
|
-601 M | $ 8.01 | -0.5 % | $ 410 M | USA |
 |
Endo International plc
ENDP
|
306 M | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
-7.43 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-524 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
Rockwell Medical
RMTI
|
-5.23 M | $ 1.03 | 1.47 % | $ 24 M | USA |
 |
HEXO Corp.
HEXO
|
-85.5 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
3.06 M | $ 3.17 | 3.93 % | $ 44.6 M | USA |
 |
Solid Biosciences
SLDB
|
-178 M | $ 6.76 | -5.32 % | $ 592 M | USA |
 |
Sundial Growers
SNDL
|
-132 M | $ 1.36 | -0.37 % | $ 3.37 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
-3.57 M | $ 2.36 | -7.45 % | $ 2.93 M | USA |
 |
Bausch Health Companies
BHC
|
2.23 B | $ 4.96 | -2.84 % | $ 1.81 B | Canada |
 |
Harrow Health
HROW
|
31.8 M | $ 35.07 | 3.15 % | $ 1.29 B | USA |
 |
OptiNose
OPTN
|
-22.3 M | - | - | $ 1.08 B | USA |
 |
Tilray
TLRY
|
-1.37 B | $ 6.49 | 0.62 % | $ 4.01 B | Canada |
 |
Evolus
EOLS
|
-25.2 M | $ 4.42 | -5.6 % | $ 285 M | USA |
 |
Veru
VERU
|
-36.6 M | $ 2.28 | -0.87 % | $ 308 M | USA |
 |
Viatris
VTRS
|
3.51 B | $ 13.41 | 0.9 % | $ 16.1 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
81.6 M | - | -39.89 % | $ 27.7 M | USA |
 |
Relmada Therapeutics
RLMD
|
-59.1 M | $ 6.04 | 3.07 % | $ 238 M | USA |
 |
OrganiGram Holdings
OGI
|
-91.8 M | $ 1.36 | -0.37 % | $ 402 M | Canada |
 |
PetIQ
PETQ
|
81.6 M | - | 1.64 % | $ 400 M | USA |
 |
PLx Pharma
PLXP
|
-40.7 M | - | -27.8 % | $ 2.56 M | USA |
 |
ProPhase Labs
PRPH
|
28.3 M | - | - | $ 5.07 M | USA |
 |
Jupiter Wellness
JUPW
|
429 K | - | - | $ 33.6 M | USA |
 |
TherapeuticsMD
TXMD
|
-7.6 M | $ 2.34 | 1.3 % | $ 24.4 M | USA |
 |
Radius Health
RDUS
|
-53.2 M | - | - | $ 1.42 B | USA |
 |
Lannett Company
LCI
|
-142 M | - | 1.15 % | $ 7.11 M | USA |
 |
cbdMD
YCBD
|
-2.86 M | $ 0.78 | 2.71 % | $ 3.36 M | USA |
 |
SCYNEXIS
SCYX
|
-16.1 M | $ 0.87 | -0.32 % | $ 43.4 M | USA |
 |
Organogenesis Holdings
ORGO
|
12.3 M | $ 2.4 | -2.63 % | $ 316 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-52.3 M | - | - | $ 193 M | Canada |
 |
Perrigo Company plc
PRGO
|
-785 M | $ 9.6 | 0.31 % | $ 1.33 B | USA |
 |
Canopy Growth Corporation
CGC
|
-95.6 M | $ 0.94 | -3.2 % | $ 101 M | Canada |
 |
Assertio Holdings
ASRT
|
8.47 M | $ 16.0 | 14.29 % | $ 102 M | USA |
 |
Recro Pharma
REPH
|
4.65 M | - | -4.76 % | $ 65.3 M | USA |
 |
Tricida
TCDA
|
-153 M | - | - | $ 3.25 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-35 M | - | - | $ 55.5 M | USA |